Arrowhead Pharmaceuticals (NASDAQ:ARWR) announces that it has earned a $25M milestone payment from collaboration partner Janssen Pharmaceuticals (NYSE:JNJ) triggered by the launch of a Phase 2b clinical trial, REEF-1, evaluating RNAi therapeutic JNJ-6379 (formerly ARO-HBV), combined with a nucleoside/tide analog, for the treatment of chronic hepatitis B virus (HBV) infection.
The primary endpoint is the 450-subject study is the proportion of participants meeting the nucleoside/tide analog treatment completion criteria at week 48. The estimated primary completion date is January 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.